Fundz

Biofrontera

WOBURN, Massachusetts, United States · Biotechnology, Healthcare, Health Care

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the pr

Key facts

Headquarters
WOBURN, Massachusetts, United States
Employees
70
Industries
Biotechnology, Healthcare, Health Care
Status
Public (BFRI)
Website
www.biofrontera.com
LinkedIn
Company page

Recent activity at Biofrontera

  • : SEC 8-K (8.01): On September 14, 2026, Biofrontera Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application concerning Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%. The approval facilitates the use of this drug in conjunction with photodynamic therapy. This significant development could enhance the company's product offerings in dermatological treatments, potentially increasing market share and revenue. The FDA's notification represents a critical milestone in the regulatory process for the company's product expansion strategy.
  • : SEC 8-K (7.01): On March 9, 2026, Biofrontera Inc. announced the results of its Phase 2b study of Ameluz® PDT for the treatment of moderate to severe Acne Vulgaris. The results were issued via a press release, which is included as Exhibit 99.1. This disclosure is part of the company's Regulation FD compliance to inform investors about significant clinical developments. The announcement highlights Biofrontera's ongoing efforts in dermatological treatments and may influence investor perception and stock valuation.
  • : SEC 8-K (8.01): On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision declaring all challenged claims of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028 to be unpatentable. This decision is part of ongoing legal proceedings that involve Biofrontera Inc. and relate to patent infringement allegations made by Sun. While Sun retains the right to seek a rehearing or appeal the Decision, the impact on current litigation in the U.S. District Court for the District of Massachusetts remains uncertain. The Company issued a press release detailing these developments on February 26, 2026, highlighting the strategic implications of these legal challenges on its operations.
  • : SEC 8-K (7.01): On February 9, 2026, Biofrontera Inc. disclosed the results of its Phase 3 study of Ameluz® PDT for the treatment of Actinic Keratoses. This announcement is significant as it pertains to the efficacy and safety of Ameluz® and could impact future market performance and regulatory approvals. The full details of the press release are included as Exhibit 99.1, which is also furnished with the filing. The study's results may influence Biofrontera's business strategy and investor confidence moving forward.
  • : SEC 8-K (8.01): On November 4, 2025, and November 6, 2025, Biofrontera Inc. received notices from Nasdaq confirming its compliance with listing requirements under Nasdaq Listing Rules 5550(b)(1) and 5550(a)(2). The November 4 notice indicated compliance due to disclosures from a prior filing, while the November 6 notice noted that the closing bid price of Biofrontera's common stock had been above $1.00 for the required period. The compliance is significant for the company as it avoids potential delisting, following earlier notices in May 2025 that highlighted deficiencies in meeting the same requirements. This indicates improved financial stability for Biofrontera Inc., which is crucial for investor confidence and market perception.
  • : SEC 8-K (1.01): On November 6, 2025, Biofrontera Inc. entered into an Asset Purchase Agreement (APA) with Pelthos Therapeutics Inc. for the sale of assets related to the Company's product, Xepi® (ozenoxacin) cream. The total purchase price is up to $10,000,000, comprising an initial payment of $3,000,000 in cash, followed by potential earnout payments based on sales milestones. A key aspect of the transaction includes a Consulting Services Agreement with a consultant who has prior experience with Xepi®, and the Company's indemnification obligations relate to this agreement. Notably, the consultant is married to Dr. Hermann Luebbert, the Company’s CEO, which adds a layer of complexity to the transaction's governance and oversight.
  • : SEC 8-K (1.01): On November 6, 2025, Biofrontera Inc. entered into an Asset Purchase Agreement (APA) with Pelthos Therapeutics Inc. for the sale of all assets relating to a specific business segment. This agreement represents a significant strategic step for Biofrontera Inc., allowing them to streamline operations and focus on core areas. The financial details regarding the transaction value have not been disclosed, but this agreement is expected to enhance Biofrontera's market position. The closing date noted is crucial as it indicates the timeline for the transaction's effectivity and subsequent integration processes.
  • : SEC 8-K (1.01):
  • : SEC 8-K (7.01): On October 23, 2025, Biofrontera Inc. announced the completion of its restructuring and asset purchase agreement with Biofrontera AG. This transaction was supported by an $11 million investment led by existing investors, suggesting a strong backing for the company's restructuring efforts. The asset purchase is anticipated to enhance Biofrontera Inc.'s operational capabilities and market position. Details regarding the specific assets acquired were not disclosed in the summary, but the involvement of significant existing investors indicates strategic confidence in the company's future direction.
  • : SEC 8-K (7.01): On October 23, 2025, Biofrontera Inc. announced the closing of its restructuring and asset purchase agreement with Biofrontera AG. This strategic move is backed by an $11 million investment led by existing investors, indicating strong support from current stakeholders. The press release detailing this information was made public, highlighting the significance of the deal and its implications for the company's financial restructuring. The event occurred on the same day as the filing, solidifying its timeliness and importance to security holders.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Biofrontera funding history

DateRoundAmount
Jun 2025Venture$11.0M
Nov 2024Seed$4.2M
Feb 2024Venture$8.0M
Oct 2022Seed$3.7M
Jul 2022Venture$7.1M

Leadership

  • John Borer, Director
  • Beth Hoffman, Director
  • Hermann Luebbert, Executive Officer, Director
  • Kevin Weber, Director
  • Loretta Wedge, Director
  • George Jones, Chief Commercial Officer
  • Jayna Gonzales, Human Resources Director
  • Fred Leffler, Chief Financial Officer

Verified email and direct lines for Biofrontera’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

Biofrontera files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Feb 2027.

Biofrontera in the news

Companies similar to Biofrontera

About Biofrontera: questions and answers

What does Biofrontera do?

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the pr

Where is Biofrontera headquartered?

Biofrontera is headquartered in WOBURN, Massachusetts, United States.

How many employees does Biofrontera have?

Biofrontera has about 70 employees.

Has Biofrontera raised funding?

Yes. Fundz has recorded 5 funding events for Biofrontera. The most recent, $11.0M, was in Jun 2025.

What is the latest news on Biofrontera?

On Oct 20, 2025, SEC 8-K (8.01): On September 14, 2026, Biofrontera Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application concerning Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%. The approval facilitates the use of this

Is Biofrontera a public company?

Yes. Biofrontera is publicly traded under the ticker BFRI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Biofrontera across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.